 Disease Progression
"Disease Progression" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
| Descriptor ID |
D018450
|
| MeSH Number(s) |
C23.550.291.656
|
| Concept/Terms |
Disease Progression- Disease Progression
- Disease Progressions
- Progression, Disease
- Progressions, Disease
|
Below are MeSH descriptors whose meaning is more general than "Disease Progression".
Below are MeSH descriptors whose meaning is more specific than "Disease Progression".
This graph shows the total number of publications written about "Disease Progression" by people in this website by year, and whether "Disease Progression" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 3 | 3 | | 1997 | 0 | 4 | 4 | | 1998 | 0 | 13 | 13 | | 1999 | 0 | 13 | 13 | | 2000 | 0 | 14 | 14 | | 2001 | 0 | 12 | 12 | | 2002 | 0 | 16 | 16 | | 2003 | 0 | 33 | 33 | | 2004 | 0 | 25 | 25 | | 2005 | 0 | 38 | 38 | | 2006 | 1 | 41 | 42 | | 2007 | 2 | 53 | 55 | | 2008 | 2 | 63 | 65 | | 2009 | 4 | 58 | 62 | | 2010 | 4 | 73 | 77 | | 2011 | 7 | 58 | 65 | | 2012 | 3 | 76 | 79 | | 2013 | 4 | 88 | 92 | | 2014 | 6 | 72 | 78 | | 2015 | 8 | 97 | 105 | | 2016 | 10 | 92 | 102 | | 2017 | 10 | 119 | 129 | | 2018 | 6 | 109 | 115 | | 2019 | 12 | 128 | 140 | | 2020 | 3 | 109 | 112 | | 2021 | 10 | 83 | 93 | | 2022 | 0 | 54 | 54 | | 2023 | 2 | 60 | 62 | | 2024 | 32 | 57 | 89 | | 2025 | 6 | 73 | 79 | | 2026 | 2 | 16 | 18 |
To return to the timeline, click here.
Below are the most recent publications written about "Disease Progression" by people in Profiles.
-
Putcha N, Bhatt SP, Bon J, Christenson SA, Han MK, Krishnan JA, Martinez FJ, Casaburi R, Crapo JD, Curtis JL, Diette GB, Dransfield MT, Eakin MN, Kalhan R, Mannino DM, Montes de Oca M, Musick H, Rowe SM, Smith BM, Salvi S, Soler X, Wedzicha JA, Wright JA, Woodruff PG, Wise RA, Chang V, Miller BE, Crim C, Drummond MB. Disease modification and progression in pre-chronic obstructive pulmonary disease: an official American Thoracic Society workshop report. Ann Am Thorac Soc. 2026 May 01; 23(5):667-688.
-
Bhargava M, Crouser ED, Barkes BQ, Weise DO, Perlman DM, Epperson LE, Griffin TJ, Jagtap PD, Mehta S, Li L, Leach SM, Maier LA. Molecular characterisation of progressive pulmonary sarcoidosis: protocol for a longitudinal multi-centre study to develop peripheral blood circulating biomarkers for predicting pulmonary sarcoidosis progression. BMJ Open. 2026 Apr 29; 16(4):e119604.
-
Carry PM, Kim S, Zwick NL, Buckner T, DeFelice B, Johnson RK, Seifert J, Waugh K, Dong F, Vanderlinden LA, Frohnert BI, Kechris K, Fiehn O, Rewers M, Norris JM. Increased Levels of the Vitamin D Metabolite Ratio Are Protective Against Progression From Islet Autoimmunity to T1D. J Clin Endocrinol Metab. 2026 Apr 22; 111(5):1438-1449.
-
Nair V, Minakawa A, Smith C, Berthier CC, Hartman J, Menon R, Fermin D, Otto EA, Gisch DL, Eadon MT, Jain S, Choi YJ, Pyle L, Eichinger F, Alakwaa FM, Rose MP, Subramanian L, El Saghir J, Beamish JA, Hodgin JB, Brosius FC, Bjornstad P, Nelson PJ, Harder JL, Werner T, Kretzler M, Schaub JA. Hypoxia inducible factor network reflects kidney disease progression in diabetes and sodium-glucose co-transporters inhibition. Signal Transduct Target Ther. 2026 Apr 21; 11(1).
-
Dahl NK, August P, Besse W, Chebib FT, Chonchol M, Cowley BD, Goral S, Guay-Woodford LM, Gulati A, Hogan MC, Lakhia R, Miskulin D, Nowak KL, Rahbari-Oskoui F, Park M, Seliger S, Yu A, Watnick T. KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Am J Kidney Dis. 2026 Apr; 87(4):447-507.
-
Chen NC, Shah VN, McQueen RB. Time in Range and Incident Diabetic Retinopathy: Clinical and Economic Evidence From Real-World Type 1 Diabetes Care. J Clin Endocrinol Metab. 2026 Mar 17; 111(4):e1146-e1152.
-
Lee J, Yekula A, Wexler A, Zhuang W, Elangovan A, Rosario J, Burger P, Ramaraju G, Addissie B, Lim N, Narkewicz MR, Twohig P. Decoding liver injury in cystic fibrosis: How to tell drug-induced liver injury from cystic fibrosis liver disease. World J Gastroenterol. 2026 Mar 14; 32(10):114946.
-
Feuerstein J, Brown E, Chahine L, Erick-Lafontant D, Gochanour C, Marshall M, Weintraub D, Simuni T, Amara A. Biological characteristics of individuals with REM sleep behavior disorder: A multicenter prospective longitudinal cohort. Parkinsonism Relat Disord. 2026 Apr; 145:108266.
-
Zhang C, Konigsberg IR, He Y, Zhang J, Chikowore T, Feldman WB, Hu X, Ding Y, Pasaniuc B, Chang D, Chen Q, Lasky-Su JA, Hecker J, Tobin MD, Chen J, Kalra S, Pratte KA, Im HK, Wan ES, Manichaikul A, Silverman EK, Bowler RP, Lange LA, Ortega VE, Martin AR, Cho MH, Moll MR. Multi-trait polygenic scores for COPD and COPD exacerbations implicate druggable proteins. JCI Insight. 2026 Apr 08; 11(7).
-
Gu W, Ren Z, Gao J, Shen Z, Wang Y, Xu L, Qian R, Miao Q, Wu Y, Hu X, Wu Y, Liu W, Wan CC, Sun L, Cai Y, Sang M, Zheng C, Yan T. Inhibiting NAT10 suppresses hepatocellular carcinoma progression by reducing Nrf2 mRNA stability and increasing oxidative stress. Chem Biol Interact. 2026 Apr 25; 429:111972.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|